BioMarin Pharmaceutical Inc. develops and markets advanced therapies for individuals with severe and life-threatening rare diseases and medical conditions. Its commercial product line includes enzyme replacement therapies for mucopolysaccharidosis IV type A and VI, as well as a synthetic oral formulation for phenylketonuria treatment. The company is now working on various clinical trials to test innovative treatments for hemophilia A, PKU, and primary hyperoxaluria.